论文部分内容阅读
通过Grayes病(GD)患者131Ⅰ治疗前后可溶性细胞凋亡相关蛋白(sFas)、肿瘤坏死因子-α(TNF-α)及可溶性 肿瘤坏死因子受体2(sTNFR2)的含量变化,研究131Ⅰ治疗与细胞凋亡的相关性及影响。用EIA法和RIA法监 测41例GD患者131Ⅰ治疗前后sFas、TNF-α和sTNFR2水平变化,根据治疗后6至8个月的临床效果,分为缓解 组27例和未缓解组14例。结果表明,治疗前,缓解组和未缓解组血清sFas、TNF-α和sTNFR2水平与对照组比 较差异有显著性(P<0．05);治疗后,缓解组血清sFas、TNF-α和sTNFR2水平与对照组比较差异无显著性(P> 0．05),未缓解组与对照组比较差异仍有显著性(P<0．05,P<0．01)。治疗前与治疗后比较,缓解组血清sFas、 TNF-α和sTNFR2差异均有显著性(P<0．01),未缓解组差异则无显著性(P>0．05)。作者认为,131Ⅰ产生的电 离辐射对患者甲状腺细胞凋亡过程产生一定影响,血清sFas、TNF-α和sTNFR2的含量变化可以作为GD患 者131Ⅰ治疗临床观测和预后判断的良好指标。
To investigate the changes of sFas, TNF-α and sTNFR2 in patients with Grayes disease (GD) before and after 131 Ⅰ treatment, The Correlation and Impact of Apoptosis. The changes of sFas, TNF-α and sTNFR2 levels in 41 GD patients before and after 131 Ⅰ treatment were monitored by EIA and RIA. According to the clinical effect of 6 to 8 months after treatment, the patients were divided into remission group (n = 27) and unrelated group (n = 14). The results showed that the levels of sFas, TNF-α and sTNFR2 in remission group and non-remission group were significantly different from those in control group before treatment (P <0.05). After treatment, the levels of sFas, TNF-α and sTNFR2 There was no significant difference between the control group and the untreated group (P <0.05, P <0.01). The difference of serum sFas, TNF-α and sTNFR2 in remission group was significant (P <0.01) before treatment and after treatment, but there was no significant difference in remission group (P> 0.05). The author believes that the 131I ionizing radiation on the process of thyroid cell apoptosis has some impact, changes in serum sFas, TNF-α and sTNFR2 levels can be used as GD in patients with 131I treatment of clinical observation and prognosis of a good indicator.